Cross-reference with related application(s) This application claims the benefit of priority based on Korean Patent Application Nos. 10-2018-0053315 and 10-2018-0053316 filed May 9, 2018, and all contents disclosed in the documents of the Korean patent application are Included as part. The present invention relates to a novel compound exhibiting enteropeptidase inhibitory activity, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for metabolic diseases such as obesity, diabetes or hyperlipidemia, including the compound or a pharmaceutically acceptable salt. 【Technology behind the invention】 Enteropeptidase is a serine protease that converts trypsinogen secreted from the pancreas after a meal into trimsin. Trypsin, activated by enteropeptidase, then activates protease precursors such as chymotrypsinogen, procarboxypeptidase and proelastase. These active form proteases break down dietary proteins into amino acid units, and the resulting amino acids are absorbed in the small intestine. Accordingly, it has been reported that enteropeptidase inhibitors can inhibit protein degradation and absorption, and are useful as drugs for treating obesity. Among the conventional oral obesity treatments, Xenical has a mechanism of action of inhibiting the action of lipolytic enzymes in the gastrointestinal tract. Due to this action, fat is not absorbed into the body and is discharged to the outside of the body. At this time, it has a side effect of seeing fat stool in a state not recognized by the phantom. On the other hand, drugs such as Bellbuck, Contrab, and Quishimia are used as treatments for obesity through an appetite suppressing action in the brain, but they have serious side effects such as depression and suicidal thoughts. In this regard, U.S. Patent Registration Nos. 9, 346, 821 treat obesity 2019/216742 1»（：1^1{2019/005997 Or a heterocyclic carboxylic acid ester derivative that exhibits serine protease inhibitory activity for prevention, and Korean Patent Laid-Open No. 10-2016-◦ 113299 discloses a fused heterocyclic compound having enteropeptidase inhibitory action and their obesity, diabetes, etc. Disclosed is the use of a therapeutic or prophylactic drug. 【Contents of the invention】 【Problem to be solved】 Under this background, it still exhibits excellent enteropeptidase inhibitory activity, and there is a need for continuous development of a compound useful for the prevention or treatment of metabolic diseases such as obesity, diabetes or hyperlipidemia. Accordingly, an object of the present invention is a novel compound or a pharmaceutically acceptable salt thereof, which has an excellent enteropeptidase inhibitory effect and is useful for the prevention or treatment of metabolic diseases such as obesity, diabetes, or hyperlipidemia, and a pharmaceutical composition comprising the same and the above To provide a method for preventing or treating metabolic diseases using a novel compound or a pharmaceutically acceptable salt thereof. 【Means to solve problems】 In order to achieve the object of the present invention as described above, a compound having the structure of the following formula (1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof is provided. The compound of formula (1) exhibits excellent enteropeptidase inhibitory activity and is useful in the treatment of various metabolic diseases such as obesity, diabetes, and hyperlipidemia. [Formula 1] One or two types selected from 2019/216742 1»（：1^1{2019/005997 A 4 to 10 membered mono or diheterocyclic group having a hetero atom; The dotted line indicates the presence or absence of a bond, Four, show 2, show 3, show 4 and show 5 are independently 0 or beep; Yo is 0 or; 犯 and seed 6 are each independently unsubstituted or substituted alkyl, and 1 to 6 together with the nitrogen atom to which it is attached form an unsubstituted or substituted 5 to 7 membered heterocyclic ring; Seed 2 is hydrogen or unsubstituted or substituted alkyl; Seed 3 and yo 4 are each independently halo or unsubstituted or substituted alkyl; Yo5 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. Regarding the "existence or absence of a bond" in the above formula (1), in the case where the bond is present, the exocyclic (6 is: (：1) of the carbon atoms of ¾1； It means that the bond between the bonded carbon atom and the exocyclic nitrogen atom forms a double bond (here, 1½1 linked to the ■11¾; exocyclic bonded to the carbon atom in the group (6 is: (:1 ) The nitrogen atom does not have an imino group as the substituent of the ¾ ). Also, preferably, it is a 5- to 9-membered mono or diheterocyclic group having one or two hetero atoms selected from the group consisting of the above and more preferably thiazole or benzothiazolyl I can. In addition, preferably, the substituent is -0 2 ) -0(0)0^, -(¾)„-0(0)0^, -((¾) (： (⑴· 15 , 0))· 3 #, and -· ¾ (⑴ may be 1 to 3 species selected from the group consisting of, wherein, and are each independently hydrogen, halo, (⑴ 0 ， (0)·^ 01-04 alkyl or phenyl, II Is an integer of 1 to 4, and the 01-04 alkyl or phenyl is unsubstituted or substituted with one or two ⑴)®。, 01-04 alkoxy, where ^ is hydrogen, 01-04 alkyl or benzyl. I can. 2019/216742 1»（：1^1{2019/005997 【Effects of the Invention】 The novel compounds according to the present invention reduce the digestive ability of proteins, lipids and sugars through excellent enteropeptidase inhibitory activity, and are useful as an agent for the treatment or prevention of various metabolic diseases such as obesity or diabetes and hyperlipidemia. 【Specific contents for carrying out the invention】 Hereinafter, the present invention will be described in more detail. The definition of each substituent used in the present specification will be described in detail. Unless otherwise specified, each substituent has the following definition. In the present specification, examples of'，halo' include fluoro, chloro, bromo, and iodo. In the present specification, "alkyl" refers to a linear or branched aliphatic saturated hydrocarbon group, preferably alkyl having 1 to 6 carbon atoms, more preferably alkyl having 1 to 4 carbon atoms. Examples of such alkyl include methyl, ethyl, propyl, isopropyl, butyl, isobutyl , 16_butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, nuclear, isonuclear, 1, 1-dimethylbutyl, 2, Includes 2-dimethylbutyl, 3, 3-dimethylbutyl and 2-ethylbutyl. In the present specification, "heterocycle" refers to an aromatic or non-aromatic ring containing a hetero atom selected from nitrogen atoms, sulfur atoms, and oxygen atoms other than carbon atoms as ring constituent atoms, and preferably 1 to 4 of the above It includes a 4 to 10 membered hetero atom, more preferably a 5 to 9 membered aromatic or non-aromatic ring. Examples of such aromatic rings include thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, 1, 2, 4 -oxadiazolyl, 1, 3, 4 -oxadiazolyl, 1, 2, 4 -thiadiazolyl, 1, 3, 4-thiadiazolyl, triazolyl, tetrazolyl, triazinyl and benzothiazolyl Includes. In addition, examples of such non-aromatic rings include tetrahydrothienyl, tetrahydrofuranyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, oxazolinyl, oxazolidinyl, pyrazolinyl, pyrazolidinyl , Thiazolinyl, 2019/216742 1»（：1/10公019/005997 Thiazolidinyl, tetrahydroisothiazolyl, tetrahydroxazolyl, tetrahydroisoxazolyl, piperidinyl, piperazinyl, tetrahydropyridinyl, dihydropyridinyl, dihydrothiopyranyl, tetrahydropyrimidinyl And tetrahydropyridazinyl, dihydropyranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, thiomorpholinyl, azepanyl, diazepanyl and azepinyl. In the present specification, "substituent" refers to an unsubstituted or substituted amino group, unsubstituted or substituted hydrocarbon group, unsubstituted or substituted, including halo, cyano group, nitro group, unsubstituted or substituted alkyl group and unsubstituted or substituted carboxyl group Substituted heterocyclic group, acyl group, unsubstituted or substituted amino group, unsubstituted or substituted carbamoyl group, unsubstituted or substituted thiocarbamoyl group, unsubstituted or substituted sulfamoyl group, unsubstituted or substituted hydroxy group And an unsubstituted or substituted sulfanyl () group and an unsubstituted or substituted silyl group. In a preferred embodiment, the compound of formula (1) may be a compound of the following formula (). [Chemical Formula 1 In the above formula, 4, show 2, show 3, show 4, and show 5 are each independently 0 or N; Yo is 0 or; And each of element 6 is independently unsubstituted or substituted alkyl, and parent 6 together with the nitrogen atom to which it is attached to form an unsubstituted or substituted 5- to 7-membered heterocyclic ring; Each of yo 3, 1 to 4 is independently bihalo or unsubstituted or substituted alkyl; 2019/216742 1»（：1^1{2019/005997 能 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. In a preferred embodiment, In the above formula (), The four, yo 2, show 3, show 4 and show 5 may be (:) independently. The above and the seedling 6 may be independently or may be unsubstituted or substituted 01-06 alkyl, more preferably H or 01-03 alkyl. In addition, the seedling 6 may form an unsubstituted or substituted 5- or 6-membered heterocyclic ring, more preferably pyrrolidinyl or piperidinyl, together with the nitrogen atom to which it is bound. In addition, Yo 3 and Myo 4 may each independently be 民 Cl, Ah, I, or unsubstituted or substituted 01-06 alkyl, more preferably 比 I ? Or unsubstituted or substituted 01-03 alkyl. In addition, the seedling 5 may be amidine, unsubstituted or substituted 01-04 alkylamine, guanidine or amide. In addition, the substituent is selected from the group consisting of -(large 九, 0 ) )01 -((:¾) (:(⑴ 0, -(¾)„- (0)· 3 !, And -· (0) 1 or more, preferably 1 to 3 types, in which case, ^ and 0 are each independently hydrogen, halo, 0))01, -0(0)^¾ (1 , 01-04 alkyl or phenyl may be And II may be an integer of 1 to 4, and the 01-04 alkyl or phenyl may be unsubstituted or substituted with one or two -(: (⑴ 0 ， 01-04 alkoxy, ^ May be hydrogen, 01-04 alkyl or benzyl. In another preferred embodiment, the compound of formula (1) is the following formula It may be a compound of (). [Formula 1 ratio 2019/216742 1»（：1^1{2019/005997 In the above formula, The dotted line indicates the presence or absence of a bond, 4, show 2, show 3, show 4, show 5, show 6, show 7 and show 8 are each independently 0 or; 0 is 0 or 財, and ]¾ are each independently unsubstituted or substituted alkyl, or 1?1 and Myo6 together with the nitrogen atom to which they are bound form an unsubstituted or substituted 5- to 7-membered heterocyclic ring; Myo2 is unsubstituted or substituted alkyl; !«, yo 4 are each independently bihalo or unsubstituted or substituted alkyl; 如 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. The dotted line in the compound of formula (¾) indicates the presence or absence of a bond, and if a bond is present, a carbon atom between and in the 5-membered hetero ring consisting of and bonded to a benzene ring and a nitrogen atom in the hetero ring Formation of a double bond between (At this time, the exocyclic nitrogen atom bonded to the carbon atom (that is, the ratio of 6 is an amino group as a substituent of the 5-membered heterocycle, and seed 2 does not exist), or a 5-membered A double bond is formed between a carbon atom and an exocyclic nitrogen atom between £ and of the heterocycle of, and the exocyclic nitrogen atom is an imino group, and the seed 6 does not exist. Preferably, formula (1) according to the present invention may be a compound of the following formula (1 1): 2019/216742 1»(：1^1{2019/005997 [Chemical Formula 11)-1] In the above formula, 4, show 2, show 3, show 4, show 5, show 6, show 7 and show 8 are each independently 0 or; 0 is 0 or And each of the seedlings 6 is independently or is an unsubstituted or substituted alkyl; And each of the seedlings 2 is independently substituted or substituted alkyl; Each of the seedlings 3 and 4 is independently bihalo or an unsubstituted or substituted alkyl; Myo5 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. Also preferably, the formula (比) according to the present invention may be a compound of the following formula (比-2): [Formula 1 2] In the above formula, 公1, Show2, Show3, Show4, Show5, Show6, Yo7 and Show8 are each independently 0 or; Yo is 0 or; 犯, and yo 6 are each independently or unsubstituted or substituted alkyl, or yo 1 and yo 6 are unsubstituted or substituted 5-membered together with the nitrogen atom to which they are attached 2019/216742 1»（：1^1{2019/005997 To form a 7 membered heterocyclic ring; Each of yo 4 is independently halo or unsubstituted or substituted alkyl; 此 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. In a preferred embodiment, In the above formulas (1), (¾-1) and (_2), The above, Show 2, Show 3, Show 4, Show 5, Show 6, Show 7 and Show 8 may each independently be (:). The seedlings 1 and 6 may each independently be II or unsubstituted or substituted 01-06 alkyl, more preferably or 01-03 alkyl ^! In addition, and yo 6 may form an unsubstituted or substituted 6-membered heterocyclic ring, more preferably piperidinyl, together with the nitrogen atom to which it is bound. In addition, it may be unsubstituted or substituted 01-06 alkyl, more preferably H or unsubstituted or substituted 01-03 alkyl. In addition, Yo 3 and Myo 4 may each independently be Hi 01,, I, or unsubstituted or substituted 01-06 alkyl, more preferably Hi or unsubstituted or substituted 01-03 alkyl. In addition, yo5 may be amidine, unsubstituted or substituted 01-04 alkylamine, guanidine, or amide. In addition, the substituent may be 01-04 alkyl, -(X⑴ Example 1 , ⑴)·' or -■'（：（0犯”, wherein, and 'are each independently hydrogen, halo, 01-04 alkyl Or it may be phenyl, and one or more such substituents, preferably 1 to 3 may be substituted. Representative compounds of formula (1) according to the present invention may include the following compounds, but are not limited thereto. 1] 3-((5-((4-carbamidoyl-2-fluorophenoxy)carbonyl)thiazole-2-yl)(ethyl)amino)propanoic acid; 2019/216742 1»(：1^1{2019/005997 2] 1-（ 5-（（ 4-carbamidoylphenoxy）carbonyl） thiazole- 2-yl） piperidine_ 4 -carboxylic acid; 3] 4-carbamidoylphenyl 2-(4-(methoxycarbonyl)piperidin-1-yl)thiazole-5-carboxylate; 4] 4-carbamidoyl-2-fluorophenyl 2-(4-(methoxycarbonyl)piperidin-1-yl)thiazole-5-carboxylate; 5] 4 -guanidinophenyl 2-(4- (methoxycarbonyl) piperidin-1 -yl) thiazole-5 -carboxylate; 6] 1- (5- ((4-guanidinophenoxy) carbonyl) thiazole-2 -yl) piperidine- 4-carboxylic acid; 7] 1-(5-((4-carbamidoyl-2-fluorophenoxy)carbonyl)thiazole-2-yl)piperidine-4-carboxylic acid; 8] 4-carbamidoylphenyl 2-((3-methoxy-3-oxopropyl) (methyl) amino) thiazole-5-carboxylate; 9] 3-((5-((4-carbamidoyl)phenoxy)carbonyl)thiazol-2-yl)(methyl)amino)propanoic acid; 10] 4-carbamidoylphenyl 2-((3-methoxy-3-oxopropyl)amino) thiazole-5-carboxylate; 11] 4-carbamidoylphenyl 2 _ ((4-methoxy- 4_oxobutyl) (methyl) amino) thiazole-5-carboxylate; 12] 4- carbamidoylphenyl 2-(ethyl(3 ··metaxy - 3_oxopropyl)amino) thiazole-5-carboxylate; 13] 3-((5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)amino)propanoic acid; 14] 3-((5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)(ethyl)amino)propanoic acid; 15] 4-((5-((4-carbamidoyl)phenoxy)carbonyl) thiazole-2-yl) (methyl) amino) butanoic acid; 16] 4 -carbamidoylphenyl 2-(3-(methoxycarbonyl)pyrrolidine- 1-yl) thiazole-5 -carboxylate; 2019/216742 1»（：1^1{2019/005997 17] 1-(5-((4-carbamidoylphenoxy)carbonyl)thiazole-2-yl)pyrrolidine_3-carboxylic acid; 18] 4-carbamidoylphenyl 2-((3-methoxy-2, 2-dimethyl- 3-oxopropyl) (methyl) amino) thiazole-5 -carboxylate; . 19] 3-((5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)(methyl)amino)-2,2-dimethylpropanoic acid; 20] 4-carbamidoyl-2 -fluorophenyl 2-(ethyl(3-methoxy-3-oxopropyl)amino)thiazole-5-carboxylate; 21] 4-carbamidoyl-2 -fluorophenyl 2-((4-methoxy-4-oxobutyl)(methyl)amino)thiazole-5-carboxylate; 22] 4-((5-((4-carbamidoyl-2-fluorophenoxy)carbonyl)thiazole-2-yl)(methyl)amino)butanoic acid; 23] Methyl 1-(5-((4-guanidinophenyl)carbamoyl)thiazole-2-yl)piperidine-4-carboxylate; 24] 4-carbamidoylphenyl 2-((3-methoxy-2,2-dimethyl-3-oxopropyl)amino) thiazole-5-carboxylate; 25] (1-（5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)piperidine-4-carbonyl)斗-aspartic acid; 2到 (1-(5-((4-carbamidoyl-2-fluorophenoxy)carbonyl)thiazole-2-yl)piperidine-4-carbonyl)-aspartate; 27] 4-carbamidoylphenyl 2-(4-(phenylcarbamoyl)piperidin-1-yl)thiazole-5-carboxylate; 28] 4 -carbamidoylphenyl 2-(4-benzamidopiperidin-1 -yl) thiazole- 5-carboxylate; 29] 4-carbamidoylphenyl 2-(4-((2-methoxy-2-oxoethyl)carbamoyl)piperidin-1-yl)thiazole-5-carboxylate; 30] 4-carbamidoylphenyl 2-(4-((3-methoxy-3-oxopropyl)carbamoyl) piperidin-1 -yl) thiazole-5-carboxylate; 31] 4 -Carbamidoylphenyl 2- (4- ((4-methoxy- 4-oxobutyl) (methyl) carbamoyl) piperidine-1 -yl) thiazole-5 -carboxylate ; 2019/216742 1»（：1^1{2019/005997 32] 4 -Carbamidoylphenyl 2- (4- ((3-methoxy-2, 2 -dimethyl- 3-oxopropyl) carbamoyl) piperidine-1 -yl) thiazole-5- Carboxylate; 33] (1_（5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)piperidine-4-carbonyl)glycine; 34] 3-(1-(5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)piperidine-4-carboxamido)propanoic acid; 35] 4-(1-(5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)-methylpiperidine-4-carboxamido)butanoic acid; 36] 3-（ 1-（ 5-（（ 4-carbamidoyl）phenoxy）carbonyl) thiazole- 2-yl) piperidine- 4 -carboxamido)- 2, 2 -dimethyl Propanoic acid; 37] 4 -carbamidoyl- 2 -fluorophenyl 2-(4-((2-methoxy-2-oxoethyl)carbamoyl)piperidine- 1 -yl) thiazole- 5 -car Boxylate; 38] 4 -Carbamidoyl-2 -Fluorophenyl 2-（4_（（3-methoxy-3_ oxopropyl）carbamoyl）piperidin-1 -yl）thiazole-5 -carboxylate ; 39] 4 _ Carbamidoyl- 2 -Pulurophenyl 2-(4-((3-methoxy-2, 2-dimethyl-3-oxopropyl)carbamoyl)piperidine-1 ) Thiazole-5-carboxylate; 40] 4 -Carbamidoyl-2 -Fluorophenyl 2-（4-（（3-methoxy-2, 2 -dimethyl-3 -oxopropyl）carbamoyl）piperidin-1 -yl) Thiazole-5-carboxylate; 41] 4 _ Carbamidoyl-2-Deluorophenyl 2- (4 _（(4 -Methoxy- 4-oxobutyl) (methyl) carbamoyl) piperidine-1 -yl) thiazole -5 -carboxylate; 42] (1- (5- ((4-carbamidoyl-2 -fluorophenoxy)carbonyl) thiazole- 2-yl) piperidine-4 -carbonyl) glycine; 43] 3-（1-（5-（（4-carbamidoyl-2 -fluorophenoxy）carbonyl）thiazole-2 -yl）piperidine-4-carboxamido）propanoic acid ; 44] 3-（1-（5-（（4-carbamidoyl-2 -fluorophenoxy）carbonyl）thiazole-2-yl）piperidine-4-carboxamido）-2， 2 -dimethylpropanoic acid; 45] 3-（1_（5-（（4-carbamidoyl-2 -fluorophenoxy）carbonyl）thiazole-2 -yl）piperidine-4-carboxamido）-2， 2 -Dimethylpropanoic acid; 46] Di-T-Butyl (3-((5-((4-carbamidoyl-2-fluorophenoxy)carbonyl)thiazole-2-yl)(ethyl)amino)propanoyl) -匕_ 2019/216742 1»（：1^1{2019/005997 Aspartate; 47] （3-（（5-（（4-carbamidoyl-2-fluorophenoxy）carbonyl）thiazole_2-yl）（ethyl）amino）propanoyl）-aspartic acid; 48] Di-T-Butyl (3-((5-((4-carbamidoyl)-2-fluorophenoxy)carbonyl)thiazole-2-yl)(ethyl)amino)propanoyl ）-1） -glutamate; 49] （3-（（5-（（4-carbamidoyl-2-fluorophenoxy）carbonyl）thiazole_ 2-yl）（ethyl）amino）propanoyl）-!)-glutamic acid ; 50] 4 -Carbamidoyl-2 -fluorophenyl 2-（ethyl（3-（（4 -(methoxycarbonyl)phenyl）amino）-3 -oxopropyl）amino）thiazole- 5-car Boxylate; 51] 4 -Carbamidoyl-2 -fluorophenyl 2-（ethyl（3-（（3- (methoxycarbonyl)phenyl）amino）-3 -oxopropyl）amino）thiazole- 5-car Boxylate; 5到 4 -Carbamidoyl-2 -Fluorophenyl 2-（（3-（（4-(thi-butoxycarbonyl)phenyl）amino）-3-oxopropyl）（ethyl）amino）thiazole -5-carboxylate; 53] 4 -carbamidoyl-2 -fluorophenyl 2-((ti-butoxycarbonyl)phenyl)amino) -3 -oxopropyl) (ethyl) amino) thiazole- 5-carboxylate; 54] 3-（3-（（5-（（4-carbamidoyl-2-fluorophenoxy）carbonyl）thiazole-2-yl）（ethyl）amino）propanamido）benzoic acid; 55] 4-（3_（（5-（(4-carbamidoyl-2-fluorophenoxy)carbonyl) thiazole-2-yl） (ethyl) amino) propanamido) benzoic acid; 56] 3-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[則thiazole-2-yl)amino)-2,2-dimethylpropanoic acid; 57] 4-carbamidoylphenyl 2-(4-(methoxycarbonyl)piperidin-1-yl)benzo[(!]thiazole-6-carboxylate; 58] 1-(6-((4-carbamidoylphenoxy)carbonyl)benzo[acid]thiazole-2-yl)piperidine-4-carboxylic acid; 2019/216742 1»（：1^1{2019/005997 59] 4-carbamidoylphenyl 2-((3-methoxy-3-oxopropyl)amino)benzo[bithiazole-6-carboxylate; 60] 4 -Carbamidoylphenyl 2- ((3-methoxy- 3-oxopropyl) (methyl) amino) benzo [則thiazole-6 -carboxylate: 61] 4-carbamidoylphenyl 2-(ethyl(3-methoxy-3-oxopropyl)amino)benzo[thiazole-6-carboxylate; 62] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[bitiazol-2-yl)(methyl)amino)propanoic acid; 63] 4-carbamidoylphenyl 2-((4-methoxy-4-oxobutyl)(methyl)amino)benzo[則thiazole-6-carboxylate; 64] 4-((6-((4-carbamidoylphenoxy)carbonyl)benzo[(!]thiazole-2-yl)(methyl)amino)butanoic acid; 65] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[則thiazol-2-yl)amino)propanoic acid; 66] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[到thiazole-2-yl)(ethyl)amino)propanoic acid; 67] 4-carbamidoylphenyl 2-((3-methoxy-2,2-dimethyl-3-oxopropyl)amino)benzo[則thiazole-6-carboxylate; 68] 4-carbamidoylphenyl 2-((3-methoxy-2, 2-dimethyl-3oxopropyl) (methyl) amino) benzo [則thiazole-6-carboxylate; 69] 4-carbamidoylphenyl 2-(ethyl(3-methoxy-2,2-dimethyl-3-oxopropyl)amino)benzo[則thiazole-6-carboxylate; 70] 4 -Carbamidoyl-2 -fluorophenyl 2-(ethyl(3-methoxy-2,2-dimethyl-3-oxopropyl)amino)benzo[bithiazole-6-carboxylate; 71] 4-carbamidoyl-2 -fluorophenyl 2-((4-methoxy-4-oxobutyl)(methyl)amino)benzo[到thiazole-6-carboxylate; 72] 4 - carbamic insignificant diagram of one-2-phenyl 2 with a full Rd - ((3-eu meteuk upon-3 _ -oxopropyl) (methyl) amino) benzo [到thiazole-6-carboxylate; 73] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[bithiazol-2-yl)amino)-2,2-dimethylpropanoic acid; 2019/216742 1»（：1^1{2019/005997 74] 3-（（6-（（4-carbamidoylphenoxy）carbonyl）benzo[(1]thiazol-2-yl)(ethyl)amino)-2,2-dimethylpropanoic acid; 75] 3-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[(!]thiazole-2 -yl)(ethyl)amino)-2,2- Dimethylpropanoic acid; 76] 4-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[bithiazole-2-yl)(methyl)amino)butanoic acid; 77] 3-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[則thiazole-2-yl)(methyl)amino)propanoic acid; 78] 4-carbamidoyl-2-fluorophenyl 2-(4-(methoxycarbonyl)piperidin-1-yl)benzo[bithiazole-6-carboxylate; 79] 1-(6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[bithiazole-2-yl)piperidine-4-carboxylic acid; 80] 4-carbamidoylphenyl 2-(4-(phenylcarbamoyl)piperidin-1-yl)benzo[(!]thiazole-6-carboxylate; 81] 4-carbamidoyl-2-fluorophenyl 2-(4-(phenylcarbamoyl)piperidin_1-yl)benzo[(!]thiazole-6-carboxylate; 82] 4-carbamidoyl-2 -fluorophenyl 2-(4-benzoamidopiperidin-1-yl)benzo[(!]thiazole-6-carboxylate; 83] 4-carbamidoylphenyl 2-(4-benzoamidopiperidin-1-yl)benzo[則thiazole-6-carboxylate; 84] 4 -carbamidoyl-2 -fluorophenyl 2-(ethyl(3-methoxy-3-oxopropyl)amino)benzo[bithiazole-6-carboxylate; 85] 3-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[到thiazole-2-yl)(ethyl)amino)propanoic acid; 86] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[bithiazol-2-yl)(methyl)amino)-2,2-dimethylpropanoic acid; 87] （幻-3-（（6-（（4-carbamidoyl-2-fluorophenoxy）carbonyl）- 3-ethylbenzo [bithiazole-2（3-ylidine）amino）- 2, 2-dimethylpropanoic acid; And 88] 4 -Carbamidoyl-2 -fluorophenyl (å)-3 -ethyl-2, 2-2019/216742 1»（：1^1{2019/005997 Dimethyl-3 -oxopropyl)imino)-2, 3 -dihydrobenzo [ ( !] thiazole- 6-carboxylate. Meanwhile, the novel compounds of the above-described embodiment may have an asymmetric carbon center, and may exist in the form of a racemate or individual optical isomers. It goes without saying that any form of isomer, including these optical isomers, may also belong to the compound category of one embodiment. The term "isomer" used below may generically refer to different compounds having the same molecular formula, and "optical isomer" may collectively refer to any stereoisomer that may exist for the compound of an embodiment, including the same geometric isomer. It is understood that in the compound of formula (1) according to one embodiment, each substituent may be attached to the chiral center of a carbon atom. And, any asymmetric carbon atom on the compound of the embodiment may exist in any form of (10 -, 比)-or uh, 幻_ coordination, and suitably each separate form 00-or 比) -Can exist in coordination. In addition, the compound of one embodiment may exist in any form of any possible isomers or mixtures thereof, for example, pure geometric isomers, diastereomers, optical isomers, racemates, or any form of a mixture thereof Can exist as In addition, when the compound of one embodiment has a double bond, each substituent bonded to the double bond may be a seedling or å configuration. In addition, when the compound of one embodiment contains a disubstituted cycloalkyl, each substituent of such cycloalkyl may have a cis or trans configuration. Meanwhile, the term “pharmaceutically acceptable salt” used below equally retains the biological effectiveness and properties of the compound of Formula (1) according to one embodiment, and is preferred in terms of pharmaceutical, biological or other properties. The salt of can be collectively referred to. Non-limiting examples of such salts include a salt in which an inorganic base or an organic base is added to the compound of Formula (1), or an acid addition salt. Examples of organic acids capable of forming such acid addition salts include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, 2019/216742 1»（：1^1{2019/005997 Ethanesulfonic acid, toluenesulfonic acid, salicylic acid, and the like. Examples of inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, or phosphoric acid. The pharmaceutically acceptable salt of the compound of the above-described embodiment may be synthesized from a free base compound or any basic or acidic moiety derived therefrom by a conventional chemical method. In addition, a second pharmaceutically acceptable salt may be synthesized from the first pharmaceutically acceptable salt. As a specific example, the acid addition salt of the compound of one embodiment may be obtained by reacting a compound in the form of a free base and a stoichiometric amount of an appropriate acid. At this time, the reaction may be carried out in water, an organic solvent, or a mixture thereof, and specifically, it may be carried out in a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile. In addition, depending on the form of the pharmaceutically acceptable salt, each form of salt can be obtained by a conventional reaction that is obvious to those skilled in the art. The compound of formula (1) of the present invention exhibits an inhibitory effect on enteropeptidase, thereby effectively inhibiting not only fat but also protein digestive enzymes in the gastrointestinal tract. Ingested foods are not absorbed into the body but are discharged out of the body, and since protein as well as fat is discharged, side effects such as fat stool are few. In addition, since it only works in the gastrointestinal tract, it has no side effects such as depression. On the other hand, according to another embodiment of the present invention, there is provided a pharmaceutical composition comprising the compound of Formula (1), isomers thereof, or a pharmaceutically acceptable salt thereof as an active ingredient, and exhibits enteropeptidase inhibitory activity. . Such a pharmaceutical composition exhibits excellent enteropeptidase inhibitory activity and can be appropriately used for the prevention or treatment of any disease related to enteropeptidase enzyme activity, for example, metabolic diseases such as obesity and diabetes. Specifically, the compound of the present invention or a pharmaceutically acceptable salt thereof is obesity based on symptomatic obesity or simple obesity, disease states or diseases associated with obesity, eating disorders, diabetes (for example, type 1 diabetes ， Type 2 diabetes, gestational diabetes, obesity type diabetes)， hyperlipidemia (for example, 2019/216742 1»（：1^1{2019/005997 Hypertriglyceridemia, hypercholesterolemia, high LDL -cholesterolemia, low HDL-cholesterolemia, postprandial hyperlipidemia), high blood pressure, heart failure, diabetic complications [for example, neuropathy, kidney disease, retinopathy, diabetic cardiomyopathy, cataract , Macrovascular disease, osteomalacia, diabetic hyperosmolar coma, infectious diseases (eg, respiratory infections, urinary tract infections, digestive tract infections, skin soft tissue infections, lower limb infections), diabetic gangrene, dry mouth, hearing impairment, cerebrovascular disorders , Peripheral blood circulation disorder], metabolic syndrome (hypertriglyceride (TG) blood, low HDL cholesterol (HDL-C) blood, high blood pressure, abdominal obesity and a disease state having three or more selected from impaired glucose tolerance), sarcopenia, It can be used as a prophylactic or therapeutic agent for reflux esophagitis. These pharmaceutical compositions can be used in the form of conventional pharmaceutical formulations. That is, the pharmaceutical composition may be administered orally or parenterally in various dosage forms at the time of actual clinical administration, and may be appropriately administered in an oral dosage form. In addition, depending on each formulation, a conventional filler, extender, binder, wetting agent, disintegrant, or diluent or excipient such as a surfactant may be further included and formulated. Solid preparations for oral administration include tablets, pills, powders, granules or capsules. These solid preparations include starch, calcium carbonate, sucrose or lactose, gelatin, etc. It may be provided by mixing with the active ingredient. In addition, in addition to the excipient, a lubricant such as magnesium stearate or talc may be used. And, as a liquid formulation for oral administration, a suspension, an inner solution, an emulsion or a syrup may be mentioned, and such a liquid formulation is a simple diluent such as water or liquid paraffin, as well as various excipients such as wetting agents, sweeteners It may contain a fragrance or preservative. In addition, preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Non-aqueous solvents may be included in these parenteral preparations, and propylene glycol, polyethylene glycol, vegetable oils such as olive oil, or injectable esters such as ethyl oleate may be used as the suspension. The base of suppositories is wi tepsol, 2019/216742 1»（：1^1{2019/005997 Macrogol, Twin Banggeunre) 61, cacao butter, laurin paper, glycerogelatin, and the like may be used. According to another embodiment of the present invention, the present invention includes administering a compound of formula (1), an isomer thereof, or a pharmaceutically acceptable salt thereof in a pharmaceutically effective amount in the form of the aforementioned pharmaceutical composition. It provides a method for inhibiting enteropeptidase, or a method for preventing or treating metabolic diseases. Terms of the present invention ''pharmaceutically effective amount 1'Means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects. The effective dose level is the patient's health condition, type of disease, severity, drug activity, Sensitivity to drugs, administration method, administration time, administration route and discharge rate, treatment period, factors including drugs used in combination or simultaneously, and other factors well known in the medical field can be determined. The pharmaceutical composition containing the compound of formula (1), isomers thereof, or pharmaceutically acceptable salts thereof of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and can be administered sequentially with conventional therapeutic agents or They can be administered simultaneously and can be single or multiple doses. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art. For example, since it may increase or decrease depending on the route of administration, the severity of the disease, sex, weight, age, etc., the dosage amount does not limit the scope of the present invention in any way. The preferred dosage of the compound of the present invention varies depending on the condition and weight of the patient, the degree of disease, the form of the drug, the route and duration of administration, but may be appropriately selected by those skilled in the art. Administration may be administered once a day or in divided doses through an oral or parenteral route. In addition, when the compound of Formula (1) of the present invention contains a thiazole ring, it can be prepared by the method of the following Scheme 1. [Scheme 1] 2019/216742 1»(：1/10公019/005997 As shown in Reaction Scheme 1, thi-butyl 2-bromobenzo[(!]thiazole_6-carboxylate (Chemical Formula 2) starting material and amino alkanoic acid (Chemical Formula (3)) were mixed with potassium carbonate The compound of formula (4) is prepared by heating in the presence of the same base, and the compound of formula (4) is further treated with an alkylhalogen such as iodoethyl in the presence of a base such as potassium carbonate. At this time, the obtained compound is selectively removed from a carboxylic acid protecting group such as t-butyl in the presence of an organic or inorganic acid such as trifluorocarboxylic acid 01) to obtain a compound of Formula 6. Subsequently, the compound of Formula 8 is prepared through a coupling reaction with the compound of Formula 7 using a coupling reagent such as ethylcarboimide hydrochloride 犯1 1 ). As a final step, the alkyl carboxylic acid ester is selectively hydrolyzed in the presence of an acid to obtain the target compound, the compound of formula (1'). On the other hand, in the case of a compound having a structure forming an unsubstituted or substituted 5 to 7 membered heterocyclic ring in the compound of formula (1) and with the nitrogen atom to which the seedling 6 is bonded, the formula (3-1) Secondary amino like compound 2019/216742 1»(：1/10公019/005997 Using alkanoic acid, it can be synthesized similarly to the method for preparing the intermediate formula 4 and prepared as a compound of formula (4-2), and a method similar to the method for preparing the compound of formula (1'), the target compound mentioned above Can be used to obtain the target compound. In addition, when the compound according to the present invention has a benzothiazole ring, it can be prepared by the following Scheme 2. [Reaction Scheme 2] As shown in Reaction Scheme 1, as a starting material, thi-butyl 2-bromobenzo[到thiazole-6-carboxylate (Chemical Formula 9)] and amino alkanoic acid (Chemical Formula 10), in the presence of a base such as potassium carbonate By heating to form the compound of formula 11 through a bonding reaction. Obtained at this time 2019/216742 1»（：1^1{2019/005997 A compound of formula 12 is obtained by selectively removing a carboxylic acid protecting group such as t-butyl in the presence of an organic or inorganic acid such as trifluorocarboxylic acid 0^. Then, the compound of formula 16 is prepared through a coupling reaction with the compound of formula 15 using a coupling reagent such as ethylcarboimide hydrochloride 1). As a last step, the target compound (Chemical Formula (1")) is obtained by selectively hydrolyzing the alkyl carboxylic acid ester in the presence of an acid. On the other hand, in order to prepare a benzothiazolylidine compound having an alkyl substituted or unsubstituted on the nitrogen of the benzothiazole ring as a substituent, the intermediate compound of Formula 11 is substituted or unsubstituted such as iodoethyl of Scheme 2 The resulting alkyl halide can be added and heated in the presence of a base such as cesium carbonate to obtain a compound of formula 13, and the obtained compound is selectively selected with a carboxylic acid protecting group such as t-butyl in the presence of an organic or inorganic acid such as trifluorocarboxylic acid. To obtain the compound of formula 7. Thereafter, the compound of Formula 17 is prepared through a coupling reaction with the compound of Formula 15 using a coupling reagent such as ethylcarboimide hydrochloride). As the last step, the target compound (Chemical Formula (1"')) is obtained by selectively hydrolyzing the alkyl carboxylic acid ester in the presence of an acid. Example Hereinafter, preferred examples and experimental examples are presented to aid in understanding the present invention. However, the following examples and experimental examples are only provided to more easily understand the present invention, and the contents of the present invention are not limited thereto. [Production Example 1] 2 -Bromothiazole-5 -carboxylic acid 2019/216742 1»（：1^1{2019/005997 After dissolving methyl 2 -bromothiazole -5 -carboxylate 20.0 § (90.0_ 0 1) in tetrahydrofuran 2501 and 50 此 of water, lithium hydroxide monohydrate 3.78 § (90.0_ 0 1) was added at room temperature. Stir for 12 hours. The reaction mixture was concentrated under reduced pressure until tetrahydrofuran was removed, and an aqueous hydrogen chloride solution was added to the remaining aqueous layer until it became 2. Ethyl acetate was added to the aqueous solution, and the organic layer was combined by extraction. The combined organic layers were dried again with sodium sulfate, and then concentrated under reduced pressure to obtain the target compound 17. (지(91%)). Table) 0\/å: 209 + ratio + [Production Example: T-butyl 2 -bromothiazole-5 -carboxylate Compound 2 obtained in [Preparation Example 1] -bromothiazole- 5-carboxylic acid 4.86 sugar (23.4_ 0 1) was dissolved in thi-butanol 311 and dichloromethane , and then di-ti-butyl dicarbonate 6.44 (28.0^01) ), (2.34^01) and pyridine 0.756此 (9.34^01) was added at room temperature and stirred for 24 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate and 0.5 aqueous hydrogen chloride solution were added until the concentration reached 6, followed by extraction twice to combine the organic layers. The combined organic layer was washed again with 0.5 aqueous sodium hydroxide solution and brine. The combined organic layers were dried over sodium sulfate and then concentrated under reduced pressure to obtain 4.89 ¾ (79%) of the target compound . 犯): 265 [¾!+¾ + 2019/216742 1»（：1^1{2019/005997 [Example 3-( (5-( (4-carbamidoyl-2 -fluorophenoxy)carbonyl) thiazole- 2-yl) (ethyl) amino) propanoic acid Step 1. T-butyl 2_ ((3_ methoxy _3_ oxo? : Non-peel) amino) thiazol-5_-carboxylate After dissolving the compound t-butyl 2-bromothiazole-5-carboxylate 2.0 g (7.57_ol) obtained in [Preparation Example 2] in 30 mL of dimethylformamide, methyl 3-aminopropanoate hydrogen chloride 1. 16 g ( 8.33mmol) and potassium carbonate 1.57g (11.36 mmol) were added at room temperature and stirred for 16 hours at 60° (:). After cooling the reaction mixture to room temperature, water was added to the reaction mixture to stop the reaction, and ethyl acetate The combined organic layer was extracted three times with brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by MPLC to give 1.8 g (83%) of the target compound as a yellow solid. MS(ESI) m/z: 287 [M+H] + Step 2. Thi-butyl 2-(ethyl (3-methoxy-3 -oxopropyl)amino)thiazole-5 -carboxylate 2019/216742 1»（：1^1{2019/005997 After dissolving the compound t-butyl 2- ((3-methoxy-3_ oxopropyl) amino) thiazole-5 -carboxylate 1.8 § (6.29_ 0 1) obtained in step 1 in dimethylformamide , potassium carbonate 1.30 §（9.43_01） and iodoethane 1. 176 §（7.54 ■） were added and stirred at 50 。（: for 5 hours. After the reaction mixture was cooled to room temperature, water was added to the reaction mixture to stop the reaction, followed by extraction with ethyl acetate three times to combine the organic layers. The combined organic layer was washed with brine, dried over sodium sulfate, concentrated under reduced pressure, and purified by: to heat the target compound as a yellow liquid 1.5 § (76%) was obtained. Tomb) /¾令: 315 [1«+1{] + Step 3. 2- (ethyl (3-methoxy-3 -oxopropyl) amino) thiazole-5 -carboxylic acid In step 2 of the imaginary machine, the 110 ^ (4 111 ¾⑴ and ½11101 (4 111 (0 3)16) were added and stirred at room temperature for 4 hours, and then for 1 hour at 70 X. The reaction mixture was concentrated under reduced pressure, and then? Purified with 11: to give the target compound 0.66 (53 «) as a white solid. 3311, ■30-(1 6 ) 5 12.19 (in 加), 9.43 (位 .41 (large), 8.0 ((1, = 6.8 ¾), 7.93 (山 2E] = 10.12 ¾), 7.76 (£, 如), 7.39 (山 1^ 1 = 8.68 ¾), 4.08-4.06 (이, 別), 3.22 (), 1.19 (3, 抑) 1.18-1.15 細,3 ; 1此(£31) ^: 459 _[] + [Experimental Example] Confirmation of enteropeptidase inhibitory activity of the compound according to the present invention The following tests were performed to measure the enteropeptidase inhibitory activity of the compound according to the present invention. Enteropeptidase inhibition assay Inhibitory activity of the synthesized Enteropeptidase inhibitor was measured using the purified Recombinant Human Enteropept idase and the substrate Acetyl-Asp-Asp-Asp-Asp-Lys-AFC (BioVision). 7.2 ng/mL Enteropeptidase, 30 \M Acetyl-Asp-Asp-Asp-Asp-Lys-AFC, various concentrations of Enteropeptidase diluted in buffer (20 mM Tris, 50 mM NaCl, pH 7.5) in a 96 well plate (Costar) Inhibitor (1% 2019/216742 1»（：1^1{2019/005997 DMS0 concentration) was dispensed so that the final volume was 100 此, and then the enzyme reaction was carried out at 30°C. Run for 1 hour. At this time, 1% DMS0, substrate, Enteropept idase, and 1% DMS0, substrate were dispensed into the positive control wells instead of the compound. Enzymatic reactions are performed in a fluorescence spectrophotometer using an excitation (exci tat ion) wavelength of 380 nm and an emission wavelength of 500 nm to increase the rate of fluorescence between 20 and 60 minutes after the start of the reaction (mi ll i-uni ts per min. ) Was measured. The fluorescence measurement value decreased by the inhibitor diluted for each concentration was converted into a relative% value for the positive control (100% reactivity) and the negative control (0% reactivity), and was used to calculate the IC 50 value. IC 5 o was calculated using PRISM (GraphPad) as the concentration of the inhibitor at which the enzyme activity was inhibited by 50%. The Ki value was calculated from the IC 5 o value using Cheng-Prusoff equat ion . [Table 1] Enteropeptidase inhibitory activity 2019/216742 1»（：1^1{2019/005997 [Table 2] Enteropeptidase inhibitory activity （:Measured but no value was obtained, Vik: Not measured） As can be seen in Tables 1 and 2 above, according to the present invention 2019/216742 1»（：1^1{2019/005997 It was confirmed that the compounds exhibit 1班¾3 and 5 inhibitory activity. As described above, it was confirmed that the compounds of the present invention exhibit excellent enteropeptidase inhibitory activity. Therefore, it can be confirmed that the compound of the present invention having enteropeptidase inhibitory activity is effective as a treatment or prevention agent for various metabolic diseases such as obesity, diabetes, and hyperlipidemia while reducing the digestive ability of proteins, lipids and sugars while having few side effects such as fatty stool. there was. 【Claim 11 A compound of the following formula (1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof: [Formula 1] In the above formula, ¾ is a 4- to 10-membered mono or diheterocyclic group having one or two heteroatoms selected from the group consisting of 凡 0 and; The dotted line indicates the presence or absence of a bond, 4, show 2, show 3, show 4 and show 5 are each independently 0 or; Yo is 0 or beep; Independently unsubstituted or substituted alkyl, or together with 1 to 1 and to form an unsubstituted or substituted 5 to 7 membered heterocyclic ring; Yo2 is hydrogen or unsubstituted or substituted alkyl; Each independently represents halo or unsubstituted or substituted alkyl; 能 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. 【Claim 2】 The method of claim 1, It is a 5- to 9-membered mono or diheterocyclic group having one or two heteroatoms selected from the group consisting of the above , a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 3】 2019/216742 1»（：1^1{2019/005997 The method of claim 1, The 加 is thiazole or benzothiazole, a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 4】 The method of claim 1, wherein the compound of formula (1) has the structure of the following formula (13), a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof: [Formula 1 In the above formula, , Show 2, show 3, show 4 and show 5 are each independently 0 or; Is 0 or N; And yo 6 is each independently unsubstituted or substituted alkyl, or yo 1 and myo 6 form an unsubstituted or substituted 5- to 7-membered heterocyclic ring together with the nitrogen atom to which they are attached; Yo 3 and Myo 4 are each independently halo or unsubstituted or substituted alkyl; Yo5 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. [Claim 5] The method of claim 4, The elements 1 and 6 are each independently unsubstituted or substituted 01-06 alkyl, and 1 to 6 may form an unsubstituted or substituted 5- or 6-membered heterocyclic ring together with the nitrogen atom to which they are attached. There is; Yo 3 and Myo 4 may each independently be }{, 01,, I, or unsubstituted or substituted 01-06 alkyl; 2019/216742 1»（：1^1{2019/005997 滿 is amidine, unsubstituted or substituted 01-04 alkylamine, guanidine or amide, a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. [Claim 6] The method of claim 4, And 1 to 6 are II or 01-03 alkyl, or parent 1 and seed 2 form pyrrolidinyl or piperidinyl together with the bonded nitrogen atom; Each of yo 3 and 1 to 4 is independently or is unsubstituted or substituted 01-03 alkyl; Yo5 is amidine, unsubstituted or substituted 01-04 alkylamine, guanidine or amide; The substituent is 1 independently selected from the group consisting of -(large, ⑴)*' _( ( ¾) ◦ (⑴ 0, -(¾)„-) , independently hydrogen, halo, (⑴ 0, -00))·。 , 01-04 alkyl or phenyl, and II is an integer of 1 to 4, and the 01-04 alkyl or phenyl is unsubstituted or substituted with 1 or 2 types of -i⑴ with 01-04 alkoxy, ^ Hydrogen, 01-04 alkyl or benzyl, a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 71 The method of claim 4, The four, show 2, show 3, yo 4 and show 5 are each independently (: phosphorus, a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. [Claim 8] The method of claim 1, wherein the compound of formula (1) is a compound represented by the following formula (1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof: [Formula 1 ratio 2019/216742 1»（：1/10公019/005997 In the above formula, The dotted line represents the presence or absence of a bond, 4, show 2, show 3, show 4, show 5, show 6, show 7 and show 8 are each independently 0 or; Yo is 0 or l; , And yo 6 are each independently unsubstituted or substituted alkyl, or 財 and 1 to 6 form an unsubstituted or substituted 5- to 7-membered heterocyclic ring together with the nitrogen atom to which it is attached; Myo2 is H or unsubstituted or substituted alkyl; !¾, 1-4 are each independently bihalo or unsubstituted or substituted alkyl; Yo5 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. The method of claim 1, Each of the above and element 6 may be independently unsubstituted or substituted 01-06 alkyl, or may be an unsubstituted or substituted 6-membered heterocyclic ring together with the nitrogen atom to which it is bound; Yo2 may be H or unsubstituted or substituted 01-06 alkyl; Seedlings 3 and 1 to 4 may each independently be 11, Cl, ， I, or unsubstituted or substituted 01-06 alkyl; Yo5 is amidine, a compound which is an unsubstituted or substituted 01-04 alkylamine, guanidine or amide, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. [Claim 9] 2019/216742 1»（：1^1{2019/005997 The method of claim 8, The seedlings 1 are independently }1 or 01-03 alkyl, or 1 to 1 and seedlings 6 form piperidinyl together with the nitrogen atom bound; 1-2 is 11 or unsubstituted or substituted 01-03 alkyl; Yo 3 and seedling 4 are each independently? Or unsubstituted or substituted 01-03 alkyl; Yo5 is amidine, unsubstituted or substituted 01-04 alkylamine, guanidine or amide; The substituents are 01-04 alkyl, -00)) (®', （⑴■' and -■' (：⑴) seed "(At this time, I?' and yo" are independently hydrogen, halo, 04 A compound having 1 to 3 selected from the group consisting of alkyl or phenyl), an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 10】 The method of claim 8, The four, show 2, show 3, show 4, show 5, show 6, show 7 and show 8 are each independently (: phosphorus, a compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 11】 The method of item 18, The formula (¾) compound is a compound represented by the following formula (：比-1), an optical isomer thereof, or a pharmaceutically acceptable salt thereof: [Formula 11)-1] In the above formula, 4, show 2, show 3, show 4, show 5, show 6, show 7 and show 8 are each independently 0 or; 2019/216742 1»（：1^1{2019/005997 Yo is 0 or beep; And each of the seedlings 6 is independently substituted or substituted alkyl; And 1 to 2 are each independently 11 or unsubstituted or substituted alkyl; Seedlings 3, 1 to 4 are each independently }1, halo, or unsubstituted or substituted alkyl; Myo5 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. 【Claim 12】 The method of claim 8, The compound of formula (:比) is a compound represented by the following formula (11)-2), an optical isomer thereof, or a pharmaceutically acceptable salt thereof: [Formula 11)-2] In the above formula, 4, show 2, show 3, show 4, show 5, show 6, show 7 and show 8 are each independently 0 or; 0 is 0 or Myo 1 and Myo 6 are each independently H or an unsubstituted or substituted alkyl, and Yo 6 together with the nitrogen atom to which it is attached form an unsubstituted or substituted 5 to 7 membered heterocyclic ring; Halo or unsubstituted or substituted alkyl; Myo5 is amidine, unsubstituted or substituted alkylamine, guanidine or amide. 【Claim 13】 2019/216742 1»(：1^1{2019/005997 The compound according to claim 1, selected from the group consisting of the following compounds 1) to 88), an optical isomer thereof, or a pharmaceutically acceptable salt thereof: 1] 3-((5-((4-carbamidoyl-2-fluorophenoxy)carbonyl)thiazole-2-yl)(ethyl)amino)propanoic acid; 2] 1-(5-((4-carbamidoylphenoxy)carbonyl)thiazole-2-yl)piperidine-4-carboxylic acid; 3] 4-carbamidoylphenyl 2-(4-(methoxycarbonyl)piperidin-1-yl)thiazole-5-carboxylate; 4] 4-carbamidoyl-2-fluorophenyl 2-(4-(methoxycarbonyl)piperidin-1-yl)thiazole-5-carboxylate; 5] 4 -guanidinophenyl 2-(4- (methoxycarbonyl) piperidin-1 -yl) thiazole-5 -carboxylate; 6] 1- (5- ((4-guanidinophenoxy) carbonyl) thiazole-2 -yl) piperidine- 4-carboxylic acid; 7] 1- (5- ((4-carbamidoyl-2 -fluorophenoxy)carbonyl) thiazole- 2-yl) piperidine-4 -carboxylic acid; 到 4-carbamidoylphenyl 2-((3-methoxy-3-oxopropyl) (methyl) amino) thiazole-5-carboxylate; 9] 3-((5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)(methyl)amino)propanoic acid; 10] 4-carbamidoylphenyl 2-((3-methoxy-3-oxopropyl)amino) thiazole-5-carboxylate; 11] 4-carbamidoylphenyl 2-((4-methoxy-4-oxobutyl)(methyl)amino)thiazole-5-carboxylate; 1到 4 -carbamidoylphenyl 2-(ethyl (3-methoxy- 3-oxopropyl) amino) thiazole-5 -carboxylate; 13] 3-((5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)amino)propanoic acid; 14] 3-（（5-（（4-carbamidoyl）phenoxy）carbonyl）thiazole- 2-2019/216742 1»（：1^1{2019/005997 One) (ethyl) amino) propanoic acid; 15] 4-（（5-（（4-carbamidoyl）phenoxy）carbonyl)thiazole-2-yl)(methyl)amino)butanoic acid; 16] 4 -carbamidoylphenyl 2-(3_(methoxycarbonyl)pyrrolidine- 1-yl) thiazole-5 -carboxylate; 17] 1-(5-((4-carbamidoylphenoxy)carbonyl)thiazole-2-yl)pyrrolidine-3-carboxylic acid; 18] 4-carbamidoylphenyl 2-((3-methoxy-2,2-dimethyl-3-oxopropyl) (methyl) amino) thiazole-5-carboxylate; 19] 3-((5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)(methyl)amino)-2,2-dimethylpropanoic acid; 20] 4-carbamidoyl-2 -fluorophenyl 2-(ethyl(3-methoxy-3-oxopropyl)amino)thiazole-5-carboxylate; 21] 4-carbamidoyl-2-fluorophenyl 2-((4-methoxy-4-oxobutyl)(methyl)amino)thiazole-5-carboxylate; 22] 4-（（5-（（4-carbamidoyl-2-fluorophenoxy）carbonyl）thiazole_2-yl）（methyl）amino）butanoic acid; 23] Methyl 1-(5-((4-guanidinophenyl)carbamoyl)thiazole-2-yl)piperidine-4-carboxylate; 24] 4-carbamidoylphenyl 2-((3-methoxy-2,2-dimethyl-3-oxopropyl)amino) thiazole-5-carboxylate; 25] (1-(5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl) piperidine-4-carbonyl)-aspartic acid; 26] (1- (5- ((4-carbamidoyl-2 -fluorophenoxy)carbonyl) thiazol-2 -yl) piperidine-4 -carbonyl)-aspartate; 27] 4-carbamidoylphenyl 2-(4-(phenylcarbamoyl)piperidin-1-yl)thiazole-5-carboxylate; 28] 4 -carbamidoylphenyl 2-(4-benzamidopiperidin-1 -yl) thiazole- 5-carboxylate; 29] 4 -Carbamidoylphenyl 2-（4-（（2-methoxy-2-2019/216742 1»（：1^1{2019/005997 Oxoethyl) carbamoyl) piperidine-1 -yl) thiazole-5 -carboxylate; 30] 4-carbamidoylphenyl 2-(4-((3-methoxy-3-oxopropyl)carbamoyl) piperidin-1 -yl) thiazole-5-carboxylate; 31] 4 -Carbamidoylphenyl 2- (4- ((4-methoxy- 4-oxobutyl) (methyl) carbamoyl) piperidine-1 -yl) thiazole-5 -carboxylate ; 32] 4 -Carbamidoylphenyl 2-(4-((3-methoxy-2, 2-dimethyl-3-oxopropyl)carbamoyl)piperidin-1 -yl)thiazole-5- Carboxylate; 33] (1-(5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)piperidine-4-carbonyl)glycine; 34] 3-（1_（5-（（4-carbamidoyl）phenoxy）carbonyl）thiazole-2-yl）piperidine-4-carboxamido）propanoic acid; 35] 4-(1-(5-((4-carbamidoyl)phenoxy)carbonyl)thiazole-2-yl)-methylpiperidine-4-carboxamido)butanoic acid; 36] 3-（1-（5-（（4-carbamidoyl）phenoxy）carbonyl）thiazole- 2-yl）piperidine- 4 -carboxamido)- 2， 2 -dimethyl Propanoic acid; 37] 4 -carbamidoyl- 2 -fluorophenyl 2-(4-((2-methoxy-2-oxoethyl)carbamoyl)piperidine- 1 -yl) thiazole- 5 -car Boxylate; 3則 4 -carbamidoyl- 2 -fluorophenyl 2-(4-((3-methoxy-3-oxopropyl)carbamoyl)piperidin-1 -yl)thiazole- 5 -car Boxylate; 39] 4 -Carbamidoyl- 2 -Fluorophenyl 2-（4-（（3-methoxy-2, 2-dimethyl_ 3-oxopropyl) carbamoyl) piperidine-1 -yl) thiazole-5 -carboxylate; 40] 4 -Carbamidoyl-2 -Fluorophenyl 2-（4-（（3-methoxy-2, 2 -dimethyl-3 -oxopropyl）carbamoyl）piperidin-1 -yl) Thiazole-5-carboxylate; 41] 4 -carbamidoyl- 2 -fluorophenyl 2-(4-((4-methoxy-4-oxobutyl)(methyl)carbamoyl)piperidin-1 -yl)thiazole- 5-carboxylate; 42] (1-(5-((4-carbamidoyl-2-fluorophenoxy)carbonyl)thiazole_2-yl) piperidine-4-carbonyl) glycine; 43] 3-(1-(5-((4-carbamidoyl-2_fluorophenoxy)carbonyl) thiazole-2 -yl) piperidine- 4-carboxamido) propanoic acid; 2019/216742 1»(：1^1{2019/005997 44] 3- (1- (5- ((4 -carbamidoyl-2-fluorophenoxy) carbonyl) thiazole-2 -yl) piperidine-4 -carboxamido)-2， 2 -dimethylpropanoic acid; 45] 3-（1-（5-（（4-carbamidoyl-2-fluorophenoxy）carbonyl）thiazole-2-yl）piperidine-4-carboxamido）-2， 2 -dimethylpropanoic acid; 46] Di-T-Butyl (3-((5-((4-carbamidoyl-2-fluorophenoxy)carbonyl)thiazole-2-yl)(ethyl)amino)propanoyl) -Aspartate; 47] (3-((5-((4-carbamidoyl-2-fluorophenoxy)carbonyl) thiazol-2-yl) (ethyl) amino) propanoyl) 斗-aspartic acid; 48] Di-T-Butyl (3-((5-((4-carbamidoyl)-2-fluorophenoxy)carbonyl)thiazole-2-yl)(ethyl)amino)propanoyl ）-1)-glutamate; 49] （3-（（5-（（4 -carbamidoyl-2 -fluorophenoxy）carbonyl）thiazole_ 2 -yl）（ethyl）amino）propanoyl）-[）-glutamic acid ; 50] 4 -Carbamidoyl-2 -fluorophenyl 2-（ethyl（3-（（4- (methoxycarbonyl)phenyl）amino）-3 -oxopropyl）amino）thiazole- 5-car Boksilate; 51] 4 -Carbamidoyl-2 -fluorophenyl 2-（ethyl（3-（（3- (methoxycarbonyl)phenyl）amino）-3 -oxopropyl）amino）thiazole- 5-car Boxylate; 52] 4 -Carbamidoyl-2 -fluorophenyl 2-（（3-（（4-(ti_butoxycarbonyl)phenyl）amino）-3-oxopropyl）（ethyl）amino）thiazole -5-carboxylate; 53] 4 -carbamidoyl-2 -fluorophenyl 2-((ter-butoxycarbonyl)phenyl)amino)-3 -oxopropyl)(ethyl)amino)thiazole- 5-carboxylate; 54] 3-(3-((5-((4-carbamidoyl-2-fluorophenoxy)carbonyl) thiazole-2-yl) (ethyl) amino) propanamido) benzoic acid; 2019/216742 1»(：1^1{2019/005997 55] 4- (3-( (5-( (4-carbamidoyl- 2-fluorophenoxy) carbonyl) thiazole- 2 -yl) (ethyl) amino) proguanamido) benzoic acid. 56] 3-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[引thiazole-2-yl)amino)-2,2-dimethylpropanoic acid; 57] 4-carbamidoylphenyl 2-(4-(methoxycarbonyl)piperidin-1-yl)benzo[(!]thiazole-6-carboxylate; 58] 1-(6-((4-carbamidoylphenoxy)carbonyl)benzo[到thiazole-2-yl)piperidine-4-carboxylic acid; 59] 4-carbamidoylphenyl 2-((3-methoxy-3-oxopropyl)amino)benzo[bithiazole-6-carboxylate; 60] 4-carbamidoylphenyl 2-((3-methoxy-3-oxopropyl) (methyl) amino) benzo[bithiazole-6-carboxylate; 61] 4-carbamidoylphenyl 2- (ethyl (3-methoxy- 3-oxopropyl) amino) benzo [sun] thiazole-6 -carboxylate: 62] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[bitiazol-2-yl)(methyl)amino)propanoic acid; 63] 4-carbamidoylphenyl 2-((4-methoxy-4-oxobutyl)(methyl)amino)benzo[則thiazole-6-carboxylate; 64] 4-((6-((4-carbamidoylphenoxy)carbonyl)benzo[bithiazol-2-yl)(methyl)amino)butanoic acid; 65] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[bithiazole-2-yl)amino)propanoic acid; 66] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[則thiazol-2-yl)(ethyl)amino)propanoic acid; 67] 4-carbamidoylphenyl 2-((3-methoxy-2,2-dimethyl-3-oxopropyl)amino)benzo[則thiazole-6-carboxylate; 68] 4-carbamidoylphenyl 2-((3-methoxy-2, 2-dimethyl- 3-oxopropyl) (methyl) amino) benzo [bithiazole-6-carboxylate; 69] 4-carbamidoylphenyl 2-(ethyl(3-methoxy-2,2-dimethyl-3-oxopropyl)amino)benzo[則thiazole-6-carboxylate; 2019/216742 1»（：1^1{2019/005997 70] 4-carbamidoyl-2 -fluorophenyl 2-(ethyl(3-methoxy-2,2-dimethyl-3-oxopropyl)amino)benzo[到thiazole-6-carboxylate; 71] 4-carbamidoyl-2 -fluorophenyl 2-((4-methoxy-4-oxobutyl)(methyl)amino)benzo[到thiazole-6-carboxylate; 72] 4 -Carbamidoyl-2-fluorophenyl 2-((3-methoxy-3-oxopropyl) (methyl) amino) benzo [(!] thiazole-6-carboxylate; 73] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[(!]thiazol-2-yl)amino)-2,2-dimethylpropanoic acid; 74] 3-（（6-（（4-carbamidoylphenoxy）carbonyl）benzo[(1]thiazol-2-yl)(ethyl)amino)-2,2-dimethylpropanoic acid; 75] 3-（（6-（（4-carbamidoyl- 2-fluorophenoxy）carbonyl）benzo [verthiazole- 2-yl) (ethyl) amino]- 2， 2-dimethylpropanoic acid ; 76] 4-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[bithiazole-2-yl)(methyl)amino)butanoic acid; 77] 3-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[bithiazole-2-yl)(methyl)amino)propanoic acid; 78] 4-carbamidoyl-2-fluorophenyl 2-(4-(methoxycarbonyl)piperidin-1-yl)benzo[bithiazole-6-carboxylate; 79] 1-(6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[到thiazole-2-yl)piperidine-4-carboxylic acid; 80] 4-carbamidoylphenyl 2-(4-(phenylcarbamoyl)piperidin-1-yl)benzo[(!]thiazole-6-carboxylate; 81] 4-carbamidoyl-2-fluorophenyl 2-(4-(phenylcarbamoyl)piperidin-1-yl)benzo[(!]thiazole-6-carboxylate; 82] 4-carbamidoyl-2 -fluorophenyl 2-(4-benzoamidopiperidin-1-yl)benzo[(!]thiazole-6-carboxylate; 83] 4-carbamidoylphenyl 2-(4-benzoamidopiperidin-1-yl)benzo[(!]thiazole-6-carboxylate; 84] 4 -Carbamidoyl-2 -Dluorophenyl 2-（Ethyl（3-methoxy-3- 2019/216742 1»（：1^1{2019/005997 Oxopropyl) amino) benzo [則 thiazole-6-carboxylate; 85] 3-((6-((4-carbamidoyl-2-fluorophenoxy)carbonyl)benzo[(!]thiazole-2-yl)(ethyl)amino)propanoic acid; 86] 3-((6-((4-carbamidoylphenoxy)carbonyl)benzo[(!]thiazol-2-yl)(methyl)amino)-2,2-dimethylpropanoic acid; 87] ½)-3-（(6-（(4-carbamidoyl-2-fluorophenoxy)carbonyl)- 3-ethylbenzo[bithiazole-2 (example)-ylidine)amino） -2, 2 -dimethylpropanoic acid; And 88] 4 -Carbamidoyl- 2 -Fluorophenyl (å)-3 -ethyl- 2- ((3-methoxy-2, 2 -dimethyl-3 -oxopropyl)imino)- 2, 3 -Dihydrobenzo [到thiazole- 6-carboxylate. 【Claim 14】 A pharmaceutical composition for inhibiting enteropeptidase comprising the compound of any one of claims 11 to 13, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 15】 A pharmaceutical composition for the prevention or treatment of metabolic diseases comprising the compound of any one of claims 1 to 13, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 16】 The pharmaceutical composition for preventing or treating metabolic diseases according to claim 15, wherein the metabolic disease is obesity, diabetes or hyperlipidemia. 【Claim 17】 A method for inhibiting enteropeptidase, comprising administering the compound of any one of claims 1 to 13, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 18】 A method for preventing or treating metabolic diseases, comprising administering the compound of any one of claims 1 to 13, an optical isomer thereof, or a pharmaceutically acceptable salt thereof. 【Claim 19】 2019/216742 1»（：1/10公019/005997 The method of claim 18, wherein the metabolic disease is obesity, diabetes or hyperlipidemia.